Researchers have found that an interaction between a mutant gene and alpha synuclein in neurons leads to hallmark pathologies seen in Parkinson’s disease, findings that may lead to new mechanisms and targets for neuroprotection.
The biomarker, the protein kinase LRRK2, is a promising candidate for future exploration.
Two members of the School of Medicine faculty have been selected as fellows for the Hedwig van Ameringen Executive Leadership in Academic Medicine® for 2016-2017.
Results show that JAK/STAT pathway inhibitors may be a new class of therapeutic treatments for patients with Parkinson’s disease. Acting by reducing inflammation, they prevent neurodegeneration in animal models and may be an important new approach to slow progression of the disease.
Preliminary results from UAB’s CBD oil studies show benefit in seizure control in some patients.
A key role for microRNA-155 in brain inflammation and neurodegeneration makes it both a potential therapeutic target and a biomarker for this progressive disorder.
More evidence that generic medications are as effective as brand name drugs.
Five faculty members in the School of Medicine have been named the 2016 class of James A. Pittman Jr., M.D., Scholars, a program organized to recognize the contributions of junior faculty and support the retention of highly competitive scientists and physician-scientists.
The Alzheimer’s plaques that accumulate around brain cells also congregate along the walls of blood vessels, according to UAB research, and that may contribute to cognitive issues.
Engineers, physicians, computer scientists and statisticians will collaborate to research and apply big data in the health care, industrial and smart cities fields.